Polycystic Ovary Syndrome: Diagnosis, Metabolic Therapy, and Fertility Management
An original evidence synthesis tracing the diagnostic pathway, insulin-sensitising and weight-directed therapy, and ovulation induction across randomized and guideline evidence.
One-Minute Takeaway on Polycystic Ovary Syndrome
One-Minute Takeaway
- Polycystic ovary syndrome is diagnosed with the 2023 evidence-based Rotterdam criteria, which now permit anti-Müllerian hormone as an alternative to ultrasound for defining polycystic ovarian morphology in adults.
- When irregular cycles and hyperandrogenism coexist, neither ultrasound nor AMH is required, simplifying diagnosis.
- For ovulation induction, randomized evidence places letrozole ahead of clomiphene, with a cumulative live birth rate of 27.5% versus 19.1% in the PPCOS II trial.
- GLP-1 receptor agonists reduce body weight and improve insulin sensitivity more than metformin, while inositols offer a tolerable insulin-sensitising option.
Why This Topic Matters
Polycystic ovary syndrome is among the most common endocrine disorders of reproductive-age women and the leading cause of anovulatory infertility. Its reach extends well beyond fertility into metabolic and cardiovascular risk.
Underdiagnosis and delayed diagnosis are common and contribute to patient distress, while overdiagnosis can generate unwarranted anxiety about infertility and metabolic disease. The clinical task is to apply consistent criteria and target the comorbidities that actually drive harm.
Three questions dominate practice: how to diagnose the condition accurately, how to manage the underlying metabolic disturbance, and how to restore fertility safely. This review synthesises the current evidence on each, anchored to the 2023 international guideline and randomized trial data.
Evidence Reviewed
This synthesis draws on the 2023 international guideline, landmark randomized trials, and multiple systematic reviews and network meta-analyses spanning diagnosis, metabolic therapy, and ovulation induction. The table below summarises the principal sources and their contribution.
| Source / Study | Design | n | Domain | Key Signal |
|---|---|---|---|---|
| Teede 2023 International Guideline | Guideline (52 SRs) | NR | Diagnosis & management | Evidence-based Rotterdam; AMH option |
| PPCOS II (Legro 2014) | Double-blind RCT | 750 | Fertility | Live birth 27.5% vs 19.1% |
| Liu 2023 meta-analysis | SR/MA of RCTs | 3,952 | Fertility | Letrozole superior across outcomes |
| GLP-1RA weight meta-analysis (2025) | SR/MA of RCTs | NR | Metabolic | GLP-1RA > metformin for weight |
| GLP-1RA vs metformin (2019) | SR/MA of 8 RCTs | 462 | Metabolic | BMI SMD −1.02; insulin sensitivity |
| Insulin sensitiser network MA | Network MA of RCTs | 1,079 | Metabolic | MI+DCI improved menses, HOMA-IR |
| Inositol SR/MA (2023) | SR/MA of 26 RCTs | 1,691 | Metabolic | Cycle normalisation, non-inferior |
| Letrozole + clomiphene SR/MA (2025) | SR/MA of RCTs | NR | Fertility | More follicles, no pregnancy gain |
Evidence quality across the field is generally low to moderate. The guideline itself notes that confidence in many recommendations remains limited, a caveat that shapes the certainty language used throughout this review.
Key Findings — Synthesised by Theme
Theme 1: Diagnosing Polycystic Ovary Syndrome
The 2023 guideline retains the Rotterdam framework but upgrades it to evidence-based criteria. In adults, two of three features are required: clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology on ultrasound or, newly, elevated AMH.
Because AMH correlates strongly with antral follicle count, the guideline now accepts it as an alternative to ultrasound for defining morphology in adults. Crucially, when irregular cycles and hyperandrogenism are both present, neither ultrasound nor AMH is needed.
The criteria yield four phenotypes, each with distinct hormonal and metabolic profiles: A (hyperandrogenism + ovulatory dysfunction + morphology), B (hyperandrogenism + ovulatory dysfunction), C (hyperandrogenism + morphology), and D (ovulatory dysfunction + morphology).
A Finnish multicentre study reported the highest AMH levels in phenotype A. Long-term outcome differences between phenotypes remain incompletely understood.
In adolescents, both hyperandrogenism and ovulatory dysfunction are required, and neither ultrasound nor AMH is recommended owing to poor specificity during puberty.
Applying updated criteria roughly halves apparent prevalence: one cohort diagnosed 29.1% with original criteria versus 16.3% with updated criteria, reducing overdiagnosis.
The guideline frames the diagnosis as potentially enduring and recommends that all affected women be assessed for cardiovascular risk factors.
This reframing shifts the clinical emphasis from a purely reproductive label toward longitudinal metabolic surveillance.
Theme 2: Metabolic Therapy
Insulin resistance is a central driver, so insulin-sensitising and weight-directed therapy is foundational. Metformin has long served as the reference insulin sensitiser but causes gastrointestinal effects that limit tolerability.
GLP-1 receptor agonists have emerged as more potent for weight and glycaemic endpoints. A 2019 meta-analysis of eight RCTs found GLP-1 receptor agonists improved insulin sensitivity (SMD −0.40, 95% CI −0.74 to −0.06) and reduced BMI (SMD −1.02) relative to metformin.
A 2025 meta-analysis extended this, showing GLP-1 receptor agonists improved BMI, body weight, waist circumference, and waist-to-hip ratio more than metformin or placebo. Combination with metformin is an option in overweight patients.
Clinical pearl: Inositols offer a tolerable middle path. A network meta-analysis found myo-inositol plus D-chiro-inositol improved menstrual frequency more than metformin (OR 14.70, 95% CI 2.31–93.58) and lowered HOMA-IR, while a 26-RCT review confirmed non-inferiority to metformin for cycle normalisation.
Theme 3: Fertility Management
For women seeking pregnancy, ovulation induction is the cornerstone. The pivotal PPCOS II trial randomized 750 women and found higher cumulative live births with letrozole than clomiphene (27.5% vs 19.1%; rate ratio 1.44, 95% CI 1.10–1.87).
Letrozole also produced higher cumulative ovulation (61.7% vs 48.3%) without raising pregnancy loss or twinning. A 29-RCT meta-analysis of 3,952 participants confirmed higher ovulation, pregnancy, and live birth rates, with a lower multiple-pregnancy risk.
Combining letrozole with clomiphene increased mature follicle and ovulation rates in a 2025 review but did not improve pregnancy rates, so monotherapy with letrozole remains the evidence-supported first step.
Quality & Consistency of the Evidence
The evidence base varies markedly in strength across the three domains. The colour-coded ratings below reflect study design, replication, and consistency.
Across domains, the strongest signal is reproductive: letrozole’s advantage is replicated and direction-consistent. Metabolic comparisons are promising but rest on shorter trials, and diagnostic refinements continue to evolve toward fuller standardisation.
What the Evidence Does Not Show
Knowledge Gaps
Several specific questions remain unresolved by current evidence:
- Long-term offspring safety of letrozole: trials were underpowered to detect congenital anomaly differences, and long-term child outcome data remain limited.
- Durability of GLP-1 receptor agonist benefit: most trials run 12–24 weeks, leaving weight maintenance and reproductive outcomes after discontinuation undefined.
- Phenotype-specific outcomes: whether the four phenotypes predict differing long-term cardiometabolic or fertility trajectories is not established.
- AMH diagnostic thresholds: population- and assay-specific cut-offs for defining morphology are not yet standardised.
- Live birth with metabolic agents: whether GLP-1 receptor agonists or inositols improve live birth, rather than surrogate markers, is unproven.
These gaps matter clinically. They explain why metabolic agents are positioned as adjuncts rather than fertility treatments, and why letrozole counselling still includes a candid note on limited long-term infant data.
Practical Implications
The evidence supports a sequenced, goal-directed approach. The considerations below frame what the data support rather than issuing directives.
Based on the current evidence, the metabolic and reproductive goals are complementary. Weight-directed therapy can improve the metabolic milieu, while letrozole addresses anovulation directly when conception is the priority.
Sequencing Note
GLP-1 receptor agonists are not used during conception attempts and require a washout before pregnancy. For women actively trying to conceive, the evidence-supported path is lifestyle plus letrozole, with metabolic agents reserved for the pre-conception or non-fertility phase.
Evidence Grade & Bottom Line
Overall Evidence Grade: Moderate to Strong (domain-dependent). Fertility evidence for letrozole is strong and replicated; metabolic and diagnostic evidence is moderate, resting partly on shorter trials and consensus, and is likely to be refined as standardisation advances.
Bottom Line
- Diagnose using the 2023 evidence-based Rotterdam criteria, with AMH as an accepted alternative to ultrasound in adults.
- When irregular cycles and hyperandrogenism coexist, additional imaging or AMH is unnecessary.
- For metabolic management, GLP-1 receptor agonists outperform metformin on weight and insulin sensitivity, with inositols a tolerable alternative.
- For fertility, letrozole is the evidence-supported first-line ovulation agent, with higher live birth and lower multiple-pregnancy risk than clomiphene.
- Long-term offspring safety, durability of metabolic benefit, and phenotype-specific outcomes remain the principal unanswered questions.
Article Information & References
Disclaimer
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
- Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. DOI: 10.1210/clinem/dgad463
- Teede HJ, Tay CT, Laven JJE, et al. Summary of the 2023 international evidence-based guideline for PCOS: an Australian perspective. Med J Aust. 2024;221(7):389–397. DOI: 10.5694/mja2.52432
- Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119–129. DOI: 10.1056/NEJMoa1313517
- Legro RS, Kunselman AR, Brzyski RG, et al. The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design. Contemp Clin Trials. 2012;33(3):470–481. DOI: 10.1016/j.cct.2011.12.005
- Liu Z, Geng Y, Huang Y, et al. Letrozole Compared With Clomiphene Citrate for Polycystic Ovarian Syndrome: A Systematic Review and Meta-analysis. Obstet Gynecol. 2023;141(3):523–534. DOI: 10.1097/AOG.0000000000005070
- Diamond MP, Legro RS, Coutifaris C, et al. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. N Engl J Med. 2015;373(13):1230–1240. DOI: 10.1056/NEJMoa1414827
- Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019;39(2):332–342. DOI: 10.1016/j.rbmo.2019.04.017
- Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Sci Rep. 2025;15:99622. DOI: 10.1038/s41598-025-99622-4
- Wang H, Zhang L, Wang Q, et al. The Antiobesity Effect of GLP-1 Receptor Agonists Alone or Combined With Metformin in Overweight/Obese Women With PCOS. Int J Endocrinol. 2021;2021:6616693. DOI: 10.1155/2021/6616693
- Greff D, Juhász AE, Váncsa S, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of RCTs. Reprod Biol Endocrinol. 2023;21:10. DOI: 10.1186/s12958-023-01055-z
- Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. J Ovarian Res. 2021;14:73. DOI: 10.1186/s13048-021-00825-w
- Letrozole and clomiphene versus letrozole alone for ovulation induction in women with PCOS: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2025;23:50. DOI: 10.1186/s12958-025-01383-2